Maude Tessier

Maude Tessier is the current Chief Business Officer at Seismic Therapeutic. Prior to this, they served as the Chief Business Officer at Ikena Oncology from July 2018 to April 2022. Before that, they were the Executive Director of Business Development & Licensing at Merck from September 2014 to July 2018. Tessier began their career in business development at Boston Children's Hospital in June 2008, where they served as the Assistant Director of Business Development and Strategic Initiatives until September 2014. Maude then held the position of Business Development Manager at Xanthus Pharmaceuticals from August 2006 to June 2008.

Maude Tessier received their Ph.D. in Molecular Biology of Cancer from the University of Toronto. Maude also holds a B.Sc. in Biochemistry from McGill University. Maude is a graduate of the International Baccalaureate program.

Maude Tessier reports to Jo Viney, Founder, President & CEO. Maude Tessier works with Nathan Higginson-Scott - Chief Technology Officer & SVP, Drug Creation, Debora Marks - Academic Founder, and John Sundy - Chief Medical Officer, Head of R&D.